The Worldwide RNA Based Therapeutic Industry is Expected to Reach $11.4 Billion by 2027


Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global RNA Based Therapeutic Market By Type, By Application, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027" report has been added to's offering.

The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during the forecast period.

RNA-based treatments have received a lot of popularity in recent years because of their potential to cure a wide range of chronic diseases like cancer, diabetes, AIDS, tuberculosis, and certain cardiovascular ailments, as well as uncommon and hereditary abnormalities. RNA-based treatments have been investigated as a viable treatment option for difficult-to-treat disorders, despite being in the clinical development phase.

The therapies are being developed using promising technologies such as RNA interference (RNAi), antisense technology, and SMaRT technology. RNAi and antisense technology are gaining popularity in the research business because they give the base sequence for developing RNA therapeutics. The potential for RNA to be employed for therapeutic purposes has been explored, and specific problems have arisen during drug discovery and the implementation of RNA therapies.

COVID-19 Impact Analysis

Coronavirus (COVID-19) was discovered in Wuhan, Hubei Province, China, in December 2019. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which can be rapidly spread between people. Moreover, this virus causes a variety of symptoms in individuals, ranging from minor to severe fever, dry cough, and exhaustion. These are some of the most prevalent symptoms. Breathing difficulties or shortness of breath, chest pain or pressure, and lack of speech or movement are all dangerous signs.

In addition, among the older population, the virus has a high risk of causing death. The World Health Organization (WHO) has declared COVID-19 a pandemic as of March 11, 2020. Furthermore, only a few vaccines have been licensed for COVID-19 in the event of an emergency.

Market Growth Factors:

An increasing number of chronic diseases and disorders

Demand is fueled by the presence of a large number of patients with infectious and chronic diseases. The desire for cures for infectious diseases and cancer is projected to influence the growth of the global RNA-based therapies and vaccine market. Moreover, according to the data shared by the WHO, Cancer is the second biggest cause of death worldwide, accounting for 9.6 million fatalities in 2018, or one in every six deaths. Men's cancers include lung, colorectal, stomach, prostate, and liver cancer, whereas women's cancers include breast, lung, cervical, colorectal, and thyroid cancer.In addition, the patient pool is large, which is expected to be another growth factor for the worldwide RNA-based therapies and vaccine market in the approaching years.

The rising popularity of personalized medicines

A large number of people are currently undergoing various drug courses as a result of a broad range of disorders. The remedies are made with a variety of salts and other ingredients and are intended for broad use. Regular drugs are supplied to clients in accordance with their treatment needs. Acids and salts, as well as other ingredients found in generic treatments, are not suitable for everyone. Due to RNA-based therapeutic, the practitioners are allowed to provide patients with personalized medicines based on their bodies' needs.

Marketing Restraining Factor:

Obstacles in the delivery of mRNA

Because mRNA is such a massive and hefty molecule (105 106 Da), successfully translating it into pharmaceuticals poses numerous problems. Additionally, mRNA is unstable and susceptible to nuclease degradation, as well as activating the immune system. In addition, because mRNA has a large negative charge density, it is less permeable across cell membranes. Because of these factors, mRNA is easily destroyed in the absence of a suitable delivery method, with a half-life of only around 7 hours. Despite the fact that chemical changes have helped to overcome some obstacles, mRNA delivery remains a challenge. Microinjection, RNA patches (mRNA loaded in a dissolving micro-needle), gene gun, protamine condensation, RNA adjuvants, and encapsulating mRNA in nanoparticles with lipids are some of the approaches that have been studied to increase mRNA delivery.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr - 2022, Jan) Leading Players

Chapter 4. Global RNA Based Therapeutic Market by Type
4.1 Global RNA Antisense Market by Region
4.2 Global RNA Interference (RNAi) Market by Region

Chapter 5. Global RNA Based Therapeutic Market by Application
5.1 Global Genetic disorders Market by Region
5.2 Global Auto immune disorders Market by Region

Chapter 6. Global RNA Based Therapeutic Market by End User
6.1 Global Research Institutes Market by Region
6.2 Global Hospitals & Clinics Market by Region

Chapter 7. Global RNA Based Therapeutic Market by Region

Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments Partnerships, Collaborations, and Agreements Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments Partnerships, Collaborations, and Agreements
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments Partnerships, Collaborations, and Agreements Approvals and Trials
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments Partnerships, Collaborations, and Agreements Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments Partnerships, Collaborations, and Agreements
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments Partnerships, Collaborations, and Agreements
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments Partnerships, Collaborations, and Agreements
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments Partnerships, Collaborations, and Agreements

For more information about this report visit